Sangeeta N. Bhatia - 08 Apr 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
08 Apr 2022
Net transactions value
-$294,612
Form type
4
Filing time
12 Apr 2022, 16:05:59 UTC
Previous filing
04 Jun 2021
Next filing
03 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $239,729 +1,907 +37% $125.71 7,098 08 Apr 2022 Direct
transaction VRTX Common Stock Sale $534,341 -1,907 -27% $280.20 5,191 08 Apr 2022 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -1,907 -100% $0.000000* 0 08 Apr 2022 Common Stock 1,907 $125.71 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1.
F2 Dr. Bhatia undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $280.20 (range $280.00 to $280.53).
F4 Fully vested.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney